Menu
← Oncology Approval Tracker
FDA DECISION ·
Inlyta + avelumab or pembrolizumab
axitinib + avelumab or pembrolizumab · Pfizer
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment of advanced renal cell carcinoma in combination with either avelumab or pembrolizumab, added to the axitinib label.
LAMPGEN ANALYSIS
Why it matters
Aligned axitinib’s own prescribing information with two combination regimens authorized on the immunotherapy labels in 2019.
What research teams should watch
Avoid double-counting the regimen’s initial 2019 approvals when comparing historical action totals.
PRIMARY RECORDS